Communiqués Evaxion A/S

Actions

EVAX

US29970R3030

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 20:34:29 25/08/2026			Varia. 5j.	Varia. 1 janv.
3,380 ^USD	-0,59%		+8,57%	-28,30%

20/08	Evaxion A/S publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/08	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent lors de la séance de jeudi	MT

Communiqués

21/08	Evaxion A/S : Interim report Q2 2026 (Presentation)	PU
20/08	Evaxion A/S : Interim report Q2 2026 (Release)	PU
20/08	Evaxion announces business update and second quarter 2026 financial results	AQ
17/08	Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program	AQ
14/08	Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026	AQ
17/07	Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026	AQ
12/07	Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1	AQ
01/07	Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop	AQ
12/06	Evaxion receives Prix Galien UK Award for Best digital health solution	AQ
11/06	Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia	AQ
12/05	Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress	AQ
07/05	Evaxion A/S : Interim report Q1 2026 (Release)	PU
07/05	Evaxion announces business update and first quarter 2026 financial results	AQ
04/05	Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026	AQ
27/04	Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer	AQ
17/04	Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial	AQ
17/04	New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma	AQ
16/04	Evaxion concludes Annual General Meeting	AQ
07/04	Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01	AQ
30/03	Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress	AQ
20/03	Notice to convene Evaxion's Annual General Meeting	AQ
19/03	Notice to convene Evaxion’s Annual General Meeting	AQ
17/03	Evaxion to present new data at AACR Annual Meeting	AQ
05/03	Evaxion A/S : Annual report 2025 (Release)	PU
05/03	Evaxion announces business update and full year 2025 financial results	AQ